[Type 2 autoimmune polyendocrine syndromes (APS-2)]. 2013

Bernard Vialettes, and Noémie Dubois-Leonardon

Type 2 autoimmune polyendocrine syndromes (APS-2) are the most frequent disorders associating several organ-specific autoimmune diseases. Their high prevalence is due to the fact that the main manifestations of APS-2, such as thyroidal autoimmunity, type 1 diabetes, autoimmune gastric atrophy and vitiligo, are common diseases. APS-2 represents a clinical model that can serve to help unravel the mechanisms underlying autoimmunity. Diagnosis of APS-2 is a challenge for the clinician, especially in poorly symptomatic forms, and may require systematic screening based on measurement of autoantibodies and functional markers.

UI MeSH Term Description Entries
D008403 Mass Screening Organized periodic procedures performed on large groups of people for the purpose of detecting disease. Screening,Mass Screenings,Screening, Mass,Screenings,Screenings, Mass
D004777 Environment The external elements and conditions which surround, influence, and affect the life and development of an organism or population. Environmental Impact,Environmental Impacts,Impact, Environmental,Impacts, Environmental,Environments
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D015551 Autoimmunity Process whereby the immune system reacts against the body's own tissues. Autoimmunity may produce or be caused by AUTOIMMUNE DISEASES. Autoimmune Response,Autoimmune Responses,Autoimmunities
D016884 Polyendocrinopathies, Autoimmune Autoimmune diseases affecting multiple endocrine organs. Type I is characterized by childhood onset and chronic mucocutaneous candidiasis (CANDIDIASIS, CHRONIC MUCOCUTANEOUS), while type II exhibits any combination of adrenal insufficiency (ADDISON'S DISEASE), lymphocytic thyroiditis (THYROIDITIS, AUTOIMMUNE;), HYPOPARATHYROIDISM; and gonadal failure. In both types organ-specific ANTIBODIES against a variety of ENDOCRINE GLANDS have been detected. The type II syndrome differs from type I in that it is associated with HLA-A1 and B8 haplotypes, onset is usually in adulthood, and candidiasis is not present. Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal-Dystrophy,Autoimmune Syndrome Type I, Polyglandular,Autoimmune Syndrome Type II, Polyglandular,Polyglandular Type I Autoimmune Syndrome,Polyglandular Type II Autoimmune Syndrome,Schmidt's Syndrome,AIRE Deficiency,APECED,APS Type 1,Autoimmune Polyendocrine Syndrome, Type 2,Autoimmune Polyendocrine Syndrome, Type II,Autoimmune Polyendocrinopathy Syndrome Type 1,Autoimmune Polyendocrinopathy with Candidiasis and Ectodermal Dystrophy,Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy,Autoimmune Polyglandular Syndrome Type I,Autoimmune Polyglandular Syndrome Type II,Autoimmune Polyglandular Syndrome Type III,Autoimmune Polyglandular Syndrome, Type 1,Autoimmune Polyglandular Syndrome, Type 3,Autoimmune Polyglandular Syndrome, Type I,Autoimmune Syndrome Type III, Polyglandular,Diabetes Mellitus, Addison Disease, Myxedema,Diabetes Mellitus, Addison's Disease, Myxedema,Multiple Endocrine Deficiency Syndrome, Type 2,Polyendocrine Autoimmune Syndrome, Type II,Polyendocrinopathy-Candidiasis-Ectodermal-Dystrophy, Autoimmune,Polyglandular Autoimmune Syndrome, Type 1,Polyglandular Autoimmune Syndrome, Type 2,Polyglandular Autoimmune Syndrome, Type 3,Polyglandular Autoimmune Syndrome, Type I,Polyglandular Deficiency Syndrome, Type 2,Polyglandular Type III Autoimmune Syndrome,Schmidt Syndrome,AIRE Deficiencies,Autoimmune Polyendocrinopathy,Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy,Deficiency, AIRE,Polyendocrinopathy Candidiasis Ectodermal Dystrophy, Autoimmune,Polyendocrinopathy, Autoimmune,Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy, Autoimmune,Syndrome, Schmidt,Syndrome, Schmidt's
D020022 Genetic Predisposition to Disease A latent susceptibility to disease at the genetic level, which may be activated under certain conditions. Genetic Predisposition,Genetic Susceptibility,Predisposition, Genetic,Susceptibility, Genetic,Genetic Predispositions,Genetic Susceptibilities,Predispositions, Genetic,Susceptibilities, Genetic

Related Publications

Bernard Vialettes, and Noémie Dubois-Leonardon
April 2003, Acta bio-medica : Atenei Parmensis,
Bernard Vialettes, and Noémie Dubois-Leonardon
May 2009, Journal of internal medicine,
Bernard Vialettes, and Noémie Dubois-Leonardon
June 2014, La Revue du praticien,
Bernard Vialettes, and Noémie Dubois-Leonardon
November 2002, Revue medicale de Liege,
Bernard Vialettes, and Noémie Dubois-Leonardon
February 2001, Clinical endocrinology,
Bernard Vialettes, and Noémie Dubois-Leonardon
January 2004, Advances in experimental medicine and biology,
Bernard Vialettes, and Noémie Dubois-Leonardon
May 2004, The New England journal of medicine,
Bernard Vialettes, and Noémie Dubois-Leonardon
June 2018, The New England journal of medicine,
Bernard Vialettes, and Noémie Dubois-Leonardon
June 2018, The New England journal of medicine,
Bernard Vialettes, and Noémie Dubois-Leonardon
June 2018, The New England journal of medicine,
Copied contents to your clipboard!